Market Place
Sourcing Support
Affordable Semaglutide & Tirzepatide GLP-1 Program Assessed
01 May 2026 //
GLOBENEWSWIRE
U.S. Prescription Drug Spending Poised To Cross $1 Trillion
30 Apr 2026 //
PR NEWSWIRE
FDA Proposes Excluding Semaglutide, Tirzepatide, Liraglutide
30 Apr 2026 //
FDA
Lilly Backs Haryana State-Fda Against Counterfeit Medicines
30 Apr 2026 //
EXPRESSPHARMA
Experts Scrutinize SkinnyRx`s GLP-1 Semaglutide Claims
23 Apr 2026 //
GLOBENEWSWIRE
Roche Backs Amylin Drug for Low-Side-Effect Obesity Care
23 Apr 2026 //
BIOSPACE
Different Packaging, Typos Expose Fake Mounjaro Racket
23 Apr 2026 //
ECONOMICTIMES
FDA issues warning letter after GLP-1 manufacturer
22 Apr 2026 //
FDA
Eli Lilly Issues Statement On Counterfeit Mounjaro Case
21 Apr 2026 //
ECONOMICTIMES
Eli Lilly flags counterfeit Mounjaro seizure in Gurugram
20 Apr 2026 //
INDPHARMAPOST
Ozempic, Mounjaro Weight-Loss Drug Demand Surges In India
19 Apr 2026 //
ECONOMICTIMES
Retatrutide Ignites Buzz on Weight Loss, Longevity
13 Apr 2026 //
ECONOMICTIMES
Mounjaro Sales Decline Due To Semaglutide Generics` Rise
10 Apr 2026 //
ECONOMICTIMES
Vanda Kicks Off NEREUS Trial for GLP-1-Induced Nausea
09 Apr 2026 //
PR NEWSWIRE
Generic Drugmakers Rush As Novo Nordisk Loses Weight-Loss Drug
09 Apr 2026 //
ECONOMICTIMES
23andMe Study Identifies Genetic Predictors of GLP-1 Weight Loss
08 Apr 2026 //
GLOBENEWSWIRE
Weight-Loss Injections Integrated Into Indian `Mounjaro Brides`
04 Apr 2026 //
ECONOMICTIMES
Lilly Taltz, Zepbound Show Strong PsA, Obesity Efficacy
28 Mar 2026 //
PR NEWSWIRE
ReflexMD Evaluates Safety Risks Of GLP-1 Claims For Semaglutide
20 Mar 2026 //
GLOBENEWSWIRE
Kroger Introduces Zepbound Kwikpen To Retail, Enhancing Access
13 Mar 2026 //
PR NEWSWIRE
Novo Nordisk Boosts Semaglutide Over Eli Lilly In Market Share
09 Mar 2026 //
ECONOMICTIMES
GoodRx To Expand Employer-Sponsored Access To Zepbound Kwikpen
06 Mar 2026 //
PHARMIWEB
Lilly Launches Employer Connect Platform With 15 Administrators
05 Mar 2026 //
PR NEWSWIRE
Ahead Of Its Time, A GLP-1 Drug Almost Made It Out Of India
04 Mar 2026 //
ECONOMICTIMES
Eli Lilly Holds Premium Price Ahead of Generic Rivals
02 Mar 2026 //
ECONOMICTIMES
What to Know Before Enrolling in MEDVi Tirzepatide GLP-1 Program
25 Feb 2026 //
GLOBENEWSWIRE
Sprout Health Unveils 2026 GLP-1 Weight Loss Program
25 Feb 2026 //
GLOBENEWSWIRE
Lilly to Launch Multi-Dose Weight-Loss Drug Device in US
24 Feb 2026 //
REUTERS
Lilly`s Taltz And Zepbound Show Superior Efficacy In Psoriasis
19 Feb 2026 //
PR NEWSWIRE
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
04 Feb 2026 //
BIOSPACE
Allurion Partners For Discounted Mounjaro Combination Therapy
03 Feb 2026 //
BUSINESSWIRE
Utide Tirzepatide, Retatrutide Clear US DMF Filing
30 Jan 2026 //
PRESS RELEASE
Skye Showcases Peripherally-Restricted CB1 Inhibitor Antibody
29 Jan 2026 //
GLOBENEWSWIRE
Skye Bioscience To Present Poster At Keystone Obesity Conference
21 Jan 2026 //
GLOBENEWSWIRE
CoreAge Rx Expands GLP-1 Access For New Year Weight Loss Goals
20 Jan 2026 //
PR NEWSWIRE
BoomRx Launches Oral Semaglutide & Tirzepatide Nationwide
14 Jan 2026 //
PR NEWSWIRE
US FDA Requests Removal of Suicide Warnings From Weight-loss Drug
13 Jan 2026 //
REUTERS
Lilly touts Zepbound-Taltz combo in patients with obesity, PsA
08 Jan 2026 //
PR NEWSWIRE
Arrowhead Pharma Reports Weight Loss in Obesity RNAi Trial
06 Jan 2026 //
BUSINESSWIRE
SkinnyRx Beats 2026 GLP-1 Prices: $199/Month Semaglutide
18 Dec 2025 //
GLOBENEWSWIRE
OrsoBio Announces Positive Data for Oral Tirzepatide TLC-6740
16 Dec 2025 //
BUSINESSWIRE
Caliway Unveils Multi-Mechanism Preclinical Research at TMASO
16 Dec 2025 //
PR NEWSWIRE
Cipla Introduces Yurpeak For Obesity, Type 2 Diabetes In India
10 Dec 2025 //
INDPHARMAPOST
Lilly looks to become innovation ‘backbone,’ exec says
08 Dec 2025 //
FIERCE BIOTECH
Eli Lilly Cuts Zepbound Price to Widen Access for Obesity Drug
01 Dec 2025 //
REUTERS
Ascletis Selects ASC37: First Oral Triple Agonist
30 Nov 2025 //
PR NEWSWIRE
Allurion Unveils Low-Dose Tirzepatide Combo Results
25 Nov 2025 //
BUSINESSWIRE
Lilly Redefines The Pharma Mega-Blockbuster
25 Nov 2025 //
BIOSPACE
India Considers Global Tenders For Key Patented Drugs Due
23 Nov 2025 //
ECONOMICTIMES
Eli Lilly Eyes Major Impact in Obesity, Diabetes
19 Nov 2025 //
ECONOMICTIMES
Eli Lilly, Novo Nordisk Strategize To Defend Top Obesity Drugs
18 Nov 2025 //
ECONOMICTIMES
Mangoceuticals Partners with Eli Lilly and Novo Nordisk
13 Nov 2025 //
GLOBENEWSWIRE
Mangoceuticals Clarifies Launch of Branded GLP-1 Programs
13 Nov 2025 //
GLOBENEWSWIRE
Trifecta Health, Trifecta Med Spa Enhance Weight Loss Treatment
11 Nov 2025 //
PR NEWSWIRE
Lilly Stitches `Queer Eye` Star Into Zepbound Campaign
11 Nov 2025 //
FIERCE PHARMA
Search For Next Blockbuster Drug Extends Beyond Weight Loss
10 Nov 2025 //
BIOSPACE
Ascletis Unveils Comprehensive Results Of ASC30 Studies
05 Nov 2025 //
PR NEWSWIRE
Needles, Pens & Pressure: The GLP-1 Challenge
05 Nov 2025 //
EXPRESSPHARMA
What`s Powering Mounjaro`s Rise To The Top Of Indian Drug Market
03 Nov 2025 //
ECONOMICTIMES
Lilly Blows Out Tirzepatide Sales Expectations, Raises Guidance
30 Oct 2025 //
FIERCE PHARMA
